Alpha Therapy with 225 Actinium Labeled Prostate Specific Membrane Antigen: Reporting New Photopeak of 78 Kilo-electron Volts for Better Image Statistics
Letter to the Editor Sir, Recent work has shown that Alpha-emitting radioisotope Actinium-225 ( 225 Ac) appears more effective than other radionuclides due to better half-life and targeted radiolabeling. [1, 2] Limited imaging data are available on the posttherapy imaging using 225 Ac labeled prostate-specific membrane antigen ( 225 Ac-PSMA) radioligand therapy in metastatic castration-resistant prostate cancer. [3] The count rate or imaging statistics can be used to enhance the image quality in posttherapy 225 Ac images to have a better image contrast for assessment of tracer localization in the target/metastatic lesions. Moreover, high image count rate is also helpful in dosimetry calculations and assessment of in-vivo biodistribution. Current literature suggests clinical imaging using two photopeaks 440 kilo-electron volts (KeV) (26.5% of 213 Bi decays to give 440 KeV) and 218 KeV during 225 Ac-PSMA therapy. [4] However, during our initial study of 225 Ac gamma-ray spectrum, it was noted that 225 Ac has a third notable photopeak of 78 KeV [ Figure 1 ], which shows higher share of photon abundance then the rest of the photopeaks, that is, 440 KeV and 218 KeV. The effective imaging potential of each peak was studied with hot-rod phantom [ Figure 2 ] using medium energy collimator as per recommendations for 225 Ac quality control. The results showed that 78 KeV peaks have significant count statistics for imaging [ Figure 2b ] when compared to prior recommended photopeaks as shown in Figure 2c . The images acquired with addition of 78 kev photo peak has better count statistics then the images taken with only two photo peaks of 440 KeV and 218 KeV. The technetium-99m phantom images were also acquired, as for 
kilo electron volts, (B) Photo peak of 218 kilo electron volts in yellow box, (C) Photo peak of 440 kilo electron volts yellow box, (D) Bremsstrahlung peak (very low abundance which is not suitable for imaging). Currently, the literature recommends 225
Ac imaging using two photo peaks, that is, 440 kilo electron volts and 218 kilo electron volts. However, it is appreciable that there is a third significant peak of 77.9 kilo electron volts which has a significant count density exemplary image of high counts for visual comparison with 225 Ac images as shown in Figure 2a .
Posttherapy images are a potential source of quality control to confirm the localization of 225 Ac-PSMA-617 in the target metastatic sites; therefore, posttherapy imaging has vital place in the management of cancer patients, especially to differentiate posttherapy flare from other possible systemic adverse effects after radionuclide therapy and to calculate organ dosimetry wherever required. It is, therefore, suggested that photopeak of 78 KeV may be included in the imaging of 225 Ac-PSMA-617 therapy to get better image quality and to perform better statistical analysis.
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